Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Plus Modified VPDL for CD20+ Adult ALL
NCT01429610Phase 2Unknown
- Sponsor
- Asan Medical Center
- Start
- Nov 2011
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in acute lymphoblastic leukemia (ALL), sponsored by Asan Medical Center. Status: unknown.
02
Drugs
rituximab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01429610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01429610.